{"id":963090,"date":"2026-05-14T16:06:09","date_gmt":"2026-05-14T20:06:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-first-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-05-14T16:06:09","modified_gmt":"2026-05-14T20:06:09","slug":"nucana-reports-first-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-first-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"NuCana Reports First Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n
\n Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026<\/em>
\n <\/strong>\n <\/p>\n

\n
\n NUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on Melanoma<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Advancing Additional Indications and Combination Strategies<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Cash Runway Expected to Extend into 2029<\/em>
\n <\/strong>\n <\/p>\n

EDINBURGH, United Kingdom, May 14, 2026 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (\u201cNuCana\u201d or the \u201cCompany\u201d) today announced financial results for the first quarter ended March 31, 2026 and provided an update on its clinical development program with its two lead anti-cancer medicines.<\/p>\n

“We are pleased to report continued progress in the first quarter of 2026 as NUC-7738 advances towards important clinical and regulatory milestones,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “During the quarter, we continued to advance enrollment for our Phase 2 NuTide:701 expansion study evaluating NUC-7738 in combination with Keytruda\u00ae (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma. The clinical activity and favorable safety profile previously reported, including confirmed objective responses and prolonged disease control, continue to support the therapeutic potential of NUC-7738 in this patient population, and we look forward to reporting final data from this study, which is expected later in 2026.”<\/p>\n

“We are also delighted to announce that the U.S. Food and Drug Administration (the \u201cFDA\u201d) cleared our Investigational New Drug application (\u201cIND\u201d) for NUC-7738 in April 2026. This important milestone enables clinical investigation of NUC-7738 in the United States and we expect our initial focus will be in patients with melanoma. We look forward to advancing our dialogue with the FDA to determine the optimal pathway toward a potential registrational strategy for NUC-7738 in melanoma.”<\/p>\n

Mr. Griffith continued, “Beyond our near-term, anticipated milestones in melanoma, we are actively exploring opportunities to broaden the clinical utility of NUC-7738 through additional indications and combination strategies. The mechanism of action of NUC-7738, disrupting RNA polyadenylation and targeting multiple aspects of the tumor microenvironment, positions it as a potentially versatile agent across a range of tumor types, and we are encouraged by the scientific rationale supporting its evaluation in new settings. We believe these efforts have the potential to significantly expand the long-term value of NUC-7738 for patients and for NuCana.”<\/p>\n

Mr. Griffith concluded, “Our strong balance sheet, with cash resources expected to fund operations into 2029, provides us with the financial flexibility to execute on our strategic priorities and advance our pipeline. We look forward to achieving important anticipated milestones throughout the remainder of 2026.”<\/p>\n

\n 2026 Anticipated Milestones<\/strong>\n <\/p>\n